Pipeline Strategy.
Tangramed’s pipeline strategy combines internal asset creation, selected partner-funded development programs, and future licensing at value inflection points.
Internal Asset Creation
We leverage our proprietary PleoBotâ„¢ platform to generate and advance rational Multimodal Therapy concepts from complex disease biology to preclinical evidence.
Partner-Funded Programs
We enter into selected partner-funded development collaborations focused on high-value opportunities where shared value creation is possible.
Strategic Value Points
Our strategy identifies future licensing, co-development, or strategic transactions at value inflection points, ensuring long-term portfolio resilience.
Current Focus: ALS.
TTangramed’s first flagship application applies Integral Therapy Design, powered by PleoBot™ prioritization and Patient Avatar Cohort robustness testing, to amyotrophic lateral sclerosis (ALS), a highly heterogeneous neurodegenerative disease where single-target approaches have delivered limited or non-durable benefit.
Why ALS
A fatal, heterogeneous disease with high unmet need, requiring a paradigm shift from monotherapy to multimodal strategies.
Objective
Develop robust Multimodal Therapy concepts applicable to the broader ALS population, focusing on biological heterogeneity.
Approach
Combining PleoBotâ„¢ prioritization and PAC robustness testing to engineer rational hypotheses through ITD design logic.
Output
Decision-ready preclinical evidence supporting the next development step for selected candidates.
How Integral Therapy Design Works
01. AI-Guided Prioritization
Integrating multi-omics, disease networks, and clinical evidence to identify high-potential therapeutic hypotheses.
02. Patient Avatar Cohort
Utilizing patient-derived iPSC models and disease-relevant human models to test robustness across biological diversity.
03. Robustness Benchmarking
Quantitative evidence supporting Go/No-Go decisions and recommended validation strategies for clinical development.
04. Decision Gate
Advance, optimize or stop selected concepts against predefined evidence thresholds.
Integral Therapy Design (ITD).
Today, ITD is most fully structured for ALS, with a defined value chain, experimental model strategy, partner network, budget logic, decision gates and development plan.
ITD is Tangramed’s proprietary framework for designing and optimizing rational Multimodal Therapies. It combines PleoBot™ prioritization, expert scientific curation and PAC robustness testing to support evidence-based development decisions.
Future Application Areas.
Neurodegenerative Diseases
Applying rational Multimodal Therapy concepts to ALS, Alzheimer's and Parkinson's, where single-target approaches have delivered limited or non-durable benefit.
Oncology
Addressing unmet needs with rational Multimodal Therapy concepts in cancer where single-target approaches need to be supported by combination strategies.
Cosmetics
Engineering Multimodal Therapies for skin aging with natural compounds, food supplements, and/or drug therapeutics.
Inflammatory Disorders
Supporting projects that target multiple inflammatory pathways simultaneously to achieve more durable clinical responses.
Cardiovascular & Metabolic disorders
Addressing cardiovascular and metabolic diseases through rational combination strategies that balance efficacy and safety.